Home>>News and Media>>News Story

Dr. Berman performs first U.S. commercial case using new FDA-approved Acessa™ technology for uterine fibroids


Jay M. Berman, M.D., FACOG a Detroit Medical Center gynecologist with the Wayne State University Physician Group, has performed the first commercial procedure in the United States using the new Acessa™ technology for the treatment of uterine fibroids at the Berry Surgery Center in Farmington Hills, an outpatient facility affiliated with the DMC Sinai-Grace Hospital.

Uterine fibroids are non-cancerous tumors that develop in the uterus. While the condition is common, symptoms vary and some women suffer severe discomfort, pain and heavy bleeding. According to the U.S. Centers for Disease Control and Prevention, fibroids are the leading cause for hysterectomy procedures worldwide.

The revolutionary Acessa™ technology is used in a minimally invasive, same-day laparoscopic procedure to deliver radiofrequency energy to fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue.

“Approximately 50 percent to 70 percent of women have uterine fibroids,” Dr. Berman said. “Before the Accessa™ technology, treatment involved cutting through layers of healthy tissue to gain access to the fibroids, or removing the uterus completely through a hysterectomy. However, research shows the majority of women choose to suffer through their symptoms rather than undergo surgery.”

Acessa™ allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and are back to regular activities within five days.

“Any technology that gives us the ability to give women choices, in this case that spares the uterus and avoids the need for hysterectomy, has merit,” said L. Andrea Coleman, M.D., chief of Obstetrics and Gynecology at DMC Sinai-Grace Hospital. “Sinai-Grace and the DMC have some of the best physicians in the country, and this is evidence of that. I applaud us for always being on the forefront of technology and for doing the work that is required to stay there.”

Dr. Berman is a board-certified gynecologist specializing in fibroid treatment and endometrial ablation. The associate professor of Obstetrics and Gynecology at the Wayne State University School of Medicine was one of 11 surgeons involved in the U.S. clinical research trials of the Acessa™ procedure, which were also conducted at the Berry Surgery Center. Dr. Berman also serves as associate chief medical officer for clinical operations for WSUPG and as director of Wayne State University School of Medicine’s Division of Gynecology.

Credit: Detroit Medical Center“We are extremely happy that Dr. Berman and the Wayne State University Physician Group have begun introducing their patients to the Acessa Procedure,” said Jeffrey M. Cohen, Halt Medical CEO. “The Acessa Procedure represents a major breakthrough in addressing one of the biggest unmet needs in women’s health, uterine fibroids. Acessa is the only medical device that can be used by gynecologists to treat all fibroid symptoms and types.”

The Acessa™ Technology was developed by Halt Medical Inc., a California-based medical device company. The U.S. Food and Drug Administration approved Acessa™ for the treatment of uterine fibroids in November.

Patients who are interested in more information about the Acessa™ procedure please call 248-352-8200.

The Wayne State University Physician Group (WSUPG) is one of southeast Michigan’s largest non-profit multi-specialty physician practice groups, with more than 2,000 physicians providing primary and specialty medical services in close to 1 million patient visits annually. WSUPG has more than 100 locations, and affiliations with the Detroit Medical Center, Oakwood Healthcare System, Karmanos Cancer Center, Crittenton Hospital Medical Center, St. Joseph Mercy Oakland and St. John Providence Health System. As faculty members of the Wayne State University School of Medicine, WSUPG’s physicians and staff are on the forefront of technology and bringing the latest in medical advancements to the bedside. In addition to its substantial clinical practice, WSUPG is training the Michigan physicians of tomorrow by providing instructors for more than 1,200 medical students and 900 residents each year. For more information or to make an appointment with a WSUPG doctor visit www.upgdocs.org. To connect with the Wayne State University Physician Group on Facebook visit www.facebook.com/wsupgdocs or on Twitter at www.twitter.com/wsupgdocs.

DMC Sinai-Grace Hospitalis a full-service hospital with 404 licensed beds and more than 700 physicians, 700 nurses, and 1,700 support staff. Services and capabilities include cardiology, emergency medicine, obstetrics and gynecology, urological services, psychiatry, radiation oncology, gerontology, physical medicine, and orthopedic surgery. Servicing more than 214,000 patients annually, Sinai-Grace also operates 25 ambulatory sites and surgery centers, including the Lahser and Berry Surgery Centers. Sinai-Grace serves as a teaching facility to more than 200 medical students each year, and is one of eight hospitals operated by the Detroit Medical Center (DMC). The DMC is proud to be the official health care services provider for the Detroit Tigers, Detroit Red Wings, and Detroit Pistons. For more information, visit www.sinaigrace.org. "Like" us on Facebook at www.facebook.com/sinaigrace or follow us on Twitter at @DMC_SinaiGrace.

Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA.  For information about the Acessa System, please visit www.haltmedical.com.

For investor relation­­­s, please contact:

Jeffrey M. Cohen, Chief Executive Officer

(925) 271-0073



Return To Previous Page